<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053495</url>
  </required_header>
  <id_info>
    <org_study_id>H-400-005</org_study_id>
    <nct_id>NCT00053495</nct_id>
  </id_info>
  <brief_title>Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination</brief_title>
  <official_title>The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and the effectiveness of a new vaccine for
      the prevention of the disease, smallpox.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to determine the minimum dose of ACAM2000 that is calculated
      to produce a major cutaneous reaction in at least 90% of a population of healthy adults 18-29
      years of age and naïve to smallpox vaccine. Specifically, the objectives of this study are
      to:

        1. Compare the safety and tolerability of four dose levels of ACAM2000 and a standard dose
           of Dryvax® in healthy adults 18-29 years of age and naïve to smallpox vaccine. Safety
           and tolerability will be determined by examination of the local cutaneous reaction,
           adverse events, physical examinations, vital signs, structured interviews, and
           laboratory analysis.

        2. Determine the immunogenicity of four dose levels of ACAM2000 and a standard dose of
           Dryvax® in healthy adults 18-29 years of age by comparing:

             1. the proportion of subjects at each dose level who develop a major cutaneous
                reaction;

             2. the proportion of subjects in each treatment group who develop neutralizing
                antibodies, including the fold-increase in antibody titer between Baseline and Day
                30 sera; and the geometric mean vaccinia neutralizing antibody titer on Day 30.

        3. Determine the minimum dose of ACAM2000 that is calculated to produce a major cutaneous
           reaction in at least 90% of a population of healthy adults 18-29 years of age and naïve
           to smallpox vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</measure>
    <time_frame>Days 0 to 30 post-vaccination</time_frame>
    <description>The severity of each reported adverse event was classified by the investigator according to the following definitions. None - no symptom; Mild - awareness of sign or symptoms, but easily tolerated; Moderate - discomfort enough to cause interference with usual activity; and Severe - incapacitating with inability to work or perform usual activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</measure>
    <time_frame>Day 30 post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With ≥ 4-fold Increase in Plaque-Reduction Neutralization Test (PRNT50) Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</measure>
    <time_frame>Day 30 post-vaccination</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants With Treatment-Emergent Rash Events Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</measure>
    <time_frame>Days 0 to 30 post-vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Chemistry Parameters (Aspartate Aminotransaminase and Alanine Aminotransferase) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</measure>
    <time_frame>Days 0 (baseline) and 15 post-vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Chemistry Parameters (Creatinine and Glucose) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</measure>
    <time_frame>Days 0 (baseline) and 15 post-vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Selected Hematology Parameters (Hematocrit, Lymphocyte, and Eosinophil) at Baseline and on Day 15 in Participants Vaccinated With ACAM2000 or Dryvax® Smallpox Vaccine.</measure>
    <time_frame>Days 0 (baseline) and 15 post-vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Selected Hematology Parameters (Red Blood Count and Platelets) at Baseline and on Day 15 in Participants Vaccinated With ACAM2000 or Dryvax® Smallpox Vaccine.</measure>
    <time_frame>Days 0 (baseline) and 15 post-vaccination</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Smallpox</condition>
  <arm_group>
    <arm_group_label>Group 1: ACAM2000 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units (PFU)/mL on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: ACAM2000 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ACAM2000 smallpox vaccine, 2.0x10-8th plaque-forming units/mL on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: ACAM2000 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: ACAM2000 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Dryvax® Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccinia virus: ACAM2000 smallpox vaccine</intervention_name>
    <description>Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml</description>
    <arm_group_label>Group 1: ACAM2000 Dose 1</arm_group_label>
    <arm_group_label>Group 2: ACAM2000 Dose 2</arm_group_label>
    <arm_group_label>Group 3: ACAM2000 Dose 3</arm_group_label>
    <arm_group_label>Group 4: ACAM2000 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>vaccinia virus (calf lymph): Dryvax</intervention_name>
    <description>Group 5 dose: 1.0x10-8th PFU/ml</description>
    <arm_group_label>Group 5: Dryvax® Vaccine</arm_group_label>
    <other_name>Dryvax®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  females must not be pregnant, lactating and must agree to use an effective form of
             birth control for the 30 days following vaccination or unable to bear children.

          -  agree to be available for the entire study and agree to comply with all requirements.

        Exclusion criteria:

          -  military service prior to 1989.

          -  history of previous smallpox vaccination.

          -  children 1 year of age or younger in the household or be in close contact

          -  smallpox vaccination within ten years

          -  known or suspected human immunodeficiency virus (HIV) infection, primary
             immunodeficiency disorder, leukemia, lymphoma, or current radiation treatment or use
             of immunosuppressive or anti-neoplastic drugs or have a household member or intimate
             contact with the conditions listed above.

          -  renal disease

          -  current or past history of eczema or a household member or direct contact who has
             eczema.

          -  known allergy or past allergic reactions to latex gloves or to antibiotics which
             include neomycin, streptomycin, chlortetracycline, and polymyxin B

          -  known allergy or past allergic reaction to blood products.

          -  known allergy to cidofovir or sulfa-containing drugs.

          -  history of allergic phenomena following smallpox vaccination in the past, including
             urticaria, erythema multiforme, or Stevens-Johnson syndrome.

          -  transfusion of blood or treatment with any blood product.

          -  current or history of drug or alcohol abuse

          -  inoculation with any other live vaccine or participating in another drug or vaccine
             trial within 30 days of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bio-Kinetic Clinical Applications</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of Rhode IslandDivision of Infectious Diseases</name>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <zip>02860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2003</study_first_submitted>
  <study_first_submitted_qc>January 30, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2003</study_first_posted>
  <results_first_submitted>January 3, 2011</results_first_submitted>
  <results_first_submitted_qc>January 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2011</results_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smallpox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 10 January 2003 to 14 April 2003 in 4 medical centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 353 participants who met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACAM2000 Dose 1</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="P2">
          <title>ACAM2000 Dose 2</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10^8th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="P3">
          <title>ACAM2000 Dose 3</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^7th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="P4">
          <title>ACAM2000 Dose 4</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10^6th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="P5">
          <title>Dryvax® Vaccine</title>
          <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACAM2000 Dose 1</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="B2">
          <title>ACAM2000 Dose 2</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10^8th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="B3">
          <title>ACAM2000 Dose 3</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^7th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="B4">
          <title>ACAM2000 Dose 4</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10^6th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="B5">
          <title>Dryvax® Vaccine</title>
          <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="101"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="49"/>
            <count group_id="B6" value="353"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="353"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="2.4"/>
                    <measurement group_id="B2" value="22" spread="3.1"/>
                    <measurement group_id="B3" value="22" spread="3.2"/>
                    <measurement group_id="B4" value="22" spread="3.0"/>
                    <measurement group_id="B5" value="22" spread="3.1"/>
                    <measurement group_id="B6" value="22" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
        <description>The severity of each reported adverse event was classified by the investigator according to the following definitions. None - no symptom; Mild - awareness of sign or symptoms, but easily tolerated; Moderate - discomfort enough to cause interference with usual activity; and Severe - incapacitating with inability to work or perform usual activity.</description>
        <time_frame>Days 0 to 30 post-vaccination</time_frame>
        <population>Adverse events were assessed in the safety, intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10^6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
          <description>The severity of each reported adverse event was classified by the investigator according to the following definitions. None - no symptom; Mild - awareness of sign or symptoms, but easily tolerated; Moderate - discomfort enough to cause interference with usual activity; and Severe - incapacitating with inability to work or perform usual activity.</description>
          <population>Adverse events were assessed in the safety, intent-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymph Node Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dehydration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pregnancy Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysuria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
        <time_frame>Day 30 post-vaccination</time_frame>
        <population>Neutralizing antibody response titers were evaluated in the antibody evaluable, per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10^6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
          <population>Neutralizing antibody response titers were evaluated in the antibody evaluable, per-protocol population.</population>
          <units>PRNT50 Titers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212" spread="536.4"/>
                    <measurement group_id="O2" value="278" spread="581.6"/>
                    <measurement group_id="O3" value="425" spread="947.4"/>
                    <measurement group_id="O4" value="582" spread="1129.3"/>
                    <measurement group_id="O5" value="1515" spread="6019.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Treatment-Emergent Rash Events Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
        <time_frame>Days 0 to 30 post-vaccination</time_frame>
        <population>Treatment-emergent rash events were assessed in the safety, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10^6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Rash Events Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
          <population>Treatment-emergent rash events were assessed in the safety, intent-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rash Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Pruritic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Pustular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Application Site Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Rash Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Chemistry Parameters (Aspartate Aminotransaminase and Alanine Aminotransferase) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
        <time_frame>Days 0 (baseline) and 15 post-vaccination</time_frame>
        <population>Clinical chemistry parameters were assessed in safety, intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10^6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Parameters (Aspartate Aminotransaminase and Alanine Aminotransferase) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
          <population>Clinical chemistry parameters were assessed in safety, intent-to-treat population</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aspartate Aminotransferase (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="7.4"/>
                    <measurement group_id="O2" value="21" spread="5.9"/>
                    <measurement group_id="O3" value="22" spread="7.1"/>
                    <measurement group_id="O4" value="23" spread="7.1"/>
                    <measurement group_id="O5" value="20" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="10.5"/>
                    <measurement group_id="O2" value="21" spread="7.7"/>
                    <measurement group_id="O3" value="22" spread="7.5"/>
                    <measurement group_id="O4" value="21" spread="6.3"/>
                    <measurement group_id="O5" value="22" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="15.0"/>
                    <measurement group_id="O2" value="32" spread="16.2"/>
                    <measurement group_id="O3" value="33" spread="17.4"/>
                    <measurement group_id="O4" value="36" spread="18.5"/>
                    <measurement group_id="O5" value="31" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="15.4"/>
                    <measurement group_id="O2" value="32" spread="17.5"/>
                    <measurement group_id="O3" value="33" spread="16.6"/>
                    <measurement group_id="O4" value="34" spread="16.2"/>
                    <measurement group_id="O5" value="33" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Chemistry Parameters (Creatinine and Glucose) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
        <time_frame>Days 0 (baseline) and 15 post-vaccination</time_frame>
        <population>Clinical chemistry parameters were assessed in safety, intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10^6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Parameters (Creatinine and Glucose) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
          <population>Clinical chemistry parameters were assessed in safety, intent-to-treat population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.147"/>
                    <measurement group_id="O2" value="0.96" spread="0.153"/>
                    <measurement group_id="O3" value="0.98" spread="0.181"/>
                    <measurement group_id="O4" value="0.97" spread="0.171"/>
                    <measurement group_id="O5" value="0.97" spread="0.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.149"/>
                    <measurement group_id="O2" value="0.98" spread="0.142"/>
                    <measurement group_id="O3" value="0.98" spread="0.169"/>
                    <measurement group_id="O4" value="1.00" spread="0.144"/>
                    <measurement group_id="O5" value="1.00" spread="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="7.3"/>
                    <measurement group_id="O2" value="84" spread="9.8"/>
                    <measurement group_id="O3" value="86" spread="7.4"/>
                    <measurement group_id="O4" value="86" spread="8.3"/>
                    <measurement group_id="O5" value="87" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="14.2"/>
                    <measurement group_id="O2" value="86" spread="14.6"/>
                    <measurement group_id="O3" value="86" spread="10.6"/>
                    <measurement group_id="O4" value="87" spread="13.2"/>
                    <measurement group_id="O5" value="88" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With ≥ 4-fold Increase in Plaque-Reduction Neutralization Test (PRNT50) Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
        <time_frame>Day 30 post-vaccination</time_frame>
        <population>Plaque-reduction neutralization test (PRNT50) titers were determined in the antibody evaluable, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10^6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With ≥ 4-fold Increase in Plaque-Reduction Neutralization Test (PRNT50) Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
          <population>Plaque-reduction neutralization test (PRNT50) titers were determined in the antibody evaluable, per-protocol population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Selected Hematology Parameters (Hematocrit, Lymphocyte, and Eosinophil) at Baseline and on Day 15 in Participants Vaccinated With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
        <time_frame>Days 0 (baseline) and 15 post-vaccination</time_frame>
        <population>Hematology parameters were evaluated in the safety, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10^6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Selected Hematology Parameters (Hematocrit, Lymphocyte, and Eosinophil) at Baseline and on Day 15 in Participants Vaccinated With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
          <population>Hematology parameters were evaluated in the safety, intent-to-treat population.</population>
          <units>Percentage (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" spread="4.20"/>
                    <measurement group_id="O2" value="43.2" spread="3.71"/>
                    <measurement group_id="O3" value="43.2" spread="4.44"/>
                    <measurement group_id="O4" value="44.2" spread="3.29"/>
                    <measurement group_id="O5" value="44.1" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" spread="3.74"/>
                    <measurement group_id="O2" value="42.3" spread="3.59"/>
                    <measurement group_id="O3" value="42.7" spread="3.21"/>
                    <measurement group_id="O4" value="43.2" spread="2.55"/>
                    <measurement group_id="O5" value="43.1" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" spread="8.26"/>
                    <measurement group_id="O2" value="31.5" spread="8.33"/>
                    <measurement group_id="O3" value="30.7" spread="7.00"/>
                    <measurement group_id="O4" value="29.6" spread="7.45"/>
                    <measurement group_id="O5" value="31.6" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="8.62"/>
                    <measurement group_id="O2" value="34.0" spread="7.41"/>
                    <measurement group_id="O3" value="34.7" spread="7.93"/>
                    <measurement group_id="O4" value="33.9" spread="6.83"/>
                    <measurement group_id="O5" value="33.8" spread="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.61"/>
                    <measurement group_id="O2" value="2.5" spread="1.95"/>
                    <measurement group_id="O3" value="2.4" spread="1.69"/>
                    <measurement group_id="O4" value="2.3" spread="1.42"/>
                    <measurement group_id="O5" value="2.4" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.07"/>
                    <measurement group_id="O2" value="2.8" spread="2.11"/>
                    <measurement group_id="O3" value="2.6" spread="1.65"/>
                    <measurement group_id="O4" value="2.7" spread="1.42"/>
                    <measurement group_id="O5" value="2.7" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Selected Hematology Parameters (Red Blood Count and Platelets) at Baseline and on Day 15 in Participants Vaccinated With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
        <time_frame>Days 0 (baseline) and 15 post-vaccination</time_frame>
        <population>Hematology parameters were evaluated in the safety, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10^6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Selected Hematology Parameters (Red Blood Count and Platelets) at Baseline and on Day 15 in Participants Vaccinated With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
          <population>Hematology parameters were evaluated in the safety, intent-to-treat population.</population>
          <units>x10-6th/μL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red Blood Cell Count (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.53"/>
                    <measurement group_id="O2" value="5.0" spread="0.47"/>
                    <measurement group_id="O3" value="5.1" spread="0.44"/>
                    <measurement group_id="O4" value="5.1" spread="0.45"/>
                    <measurement group_id="O5" value="5.1" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell Count (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.50"/>
                    <measurement group_id="O2" value="4.9" spread="0.44"/>
                    <measurement group_id="O3" value="5.0" spread="0.39"/>
                    <measurement group_id="O4" value="5.0" spread="0.37"/>
                    <measurement group_id="O5" value="5.0" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274" spread="64.0"/>
                    <measurement group_id="O2" value="282" spread="60.1"/>
                    <measurement group_id="O3" value="281" spread="68.1"/>
                    <measurement group_id="O4" value="274" spread="52.4"/>
                    <measurement group_id="O5" value="267" spread="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284" spread="58.6"/>
                    <measurement group_id="O2" value="280" spread="57.7"/>
                    <measurement group_id="O3" value="281" spread="65.1"/>
                    <measurement group_id="O4" value="284" spread="59.3"/>
                    <measurement group_id="O5" value="285" spread="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination for up to 6 months post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ACAM2000 Dose 1</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="E2">
          <title>ACAM2000 Dose 2</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10^8th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="E3">
          <title>ACAM2000 Dose 3</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10^7th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="E4">
          <title>ACAM2000 Dose 4</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10^6th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="E5">
          <title>Dryvax® Vaccine</title>
          <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10^8th plaque-forming units/mL on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy Not Otherwise Specified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymph Node Pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhea Not Otherwise Specified</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting Not Otherwise Specified</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache Not Otherwise Specified</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Not Otherwise Specified</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eddie Darton, Medical Director</name_or_title>
      <organization>Emergent BioSolutions</organization>
      <phone>240-631-3688</phone>
      <email>dartone@ebsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

